Malignant cells constitutively express Natural killer group 2, member D (NKG2D) or DNAX Accessory Molecule-1 (DNAM-1) ligands, yet they are often unable to trigger a robust cytotoxic cell response. It may be therapeutically useful to implement strategies aimed at increasing the density of NKG2D and DNAM-1 ligands on the surface of cancer cells, endowing them with the capacity to activate potent antitumor natural killer-cell responses. © 2013 Landes Bioscience.
Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma / Soriani, Alessandra; Fionda, Cinzia; Ricci, Biancamaria; Maria Luisa, Iannitto; Cippitelli, Marco; Santoni, Angela. - In: ONCOIMMUNOLOGY. - ISSN 2162-4011. - 2:12(2013), pp. e26663-1-e26663-3. [10.4161/onci.26663]
Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma
SORIANI, Alessandra;FIONDA, Cinzia;RICCI, BIANCAMARIA;CIPPITELLI, Marco;SANTONI, Angela
2013
Abstract
Malignant cells constitutively express Natural killer group 2, member D (NKG2D) or DNAX Accessory Molecule-1 (DNAM-1) ligands, yet they are often unable to trigger a robust cytotoxic cell response. It may be therapeutically useful to implement strategies aimed at increasing the density of NKG2D and DNAM-1 ligands on the surface of cancer cells, endowing them with the capacity to activate potent antitumor natural killer-cell responses. © 2013 Landes Bioscience.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
